title: Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig.
abstract: Certain skin pathologies, including psoriasis, are thought to be immune-mediated inflammatory diseases. Available literature clearly indicates the involvement of inflammatory cells (neutrophils, T cells, and macrophages), their cytokines, and the p38 mitogen-activated protein kinase (MAPK) signaling pathway in the pathophysiology of psoriasis. Neutrophils play an important role in the formation of acute inflammatory changes in psoriasis. Acute inflammation or acute flares in psoriasis remain poorly addressed in clinical medicine. In this communication, we first establish a simple and reproducible model for studying neutrophil-mediated acute skin inflammation. Using the hairless guinea pig, due to the similarity of skin architecture to that of human, acute inflammation was induced with an intradermal injection of 50 μg/mL lipopolysaccharide (LPS) in 50 μL solution. Myeloperoxidase (MPO) activity was measured by MPO-positive neutrophils and shown to increase for 24-hours post-injection. Simultaneously, the level of phosphorylated p38 MAPK was documented for 48-hours post-LPS injection in the skin. Next, we used this model to examine the therapeutic potential of an α-selective p38 MAPK inhibitor, SCIO-469. A comparison of topical application of SCIO-469 at 5 mg/mL or 15 mg/mL to vehicle revealed that SCIO-469 dose-dependently reduces acute skin inflammation and that this effect is statistically significant at the higher dose. Further examination of tissues that received this dose also revealed statistically significant reduction of MPO activity, phosphorylated p38 MAPK, interleukin-6, and cyclooxygenase-2. These data suggest that the α-selective p38 MAPK inhibitor, SCIO-469, acts as a topical anti-inflammatory agent via the p38 MAPK pathway to reduce neutrophil induced acute inflammation in the skin. These observations suggest that α-selective p38 MAPK inhibition may be an effective therapeutic strategy to manage acute skin inflammation.
authors.affiliation: Scios Inc, Fremont, CA, USA.
authors.forename: Satyanarayana
authors.initials: S
authors.lastname: Medicherla
authors.forename: Jing Ying
authors.initials: JY
authors.lastname: Ma
authors.forename: Mamtha
authors.initials: M
authors.lastname: Reddy
authors.forename: Irina
authors.initials: I
authors.lastname: Esikova
authors.forename: Irene
authors.initials: I
authors.lastname: Kerr
authors.forename: Fabiola
authors.initials: F
authors.lastname: Movius
authors.forename: Linda S
authors.initials: LS
authors.lastname: Higgins
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Protter
references.citation: Br J Dermatol. 2005 Dec;153(6):1114-20
references.pmid: 16307645
references.citation: J Pharmacol Exp Ther. 2006 Jul;318(1):132-41
references.pmid: 16597712
references.citation: Pain. 2009 Mar;142(1-2):116-26
references.pmid: 19167815
references.citation: Curr Opin Drug Discov Devel. 2005 Jul;8(4):421-30
references.pmid: 16022178
references.citation: Biochem Biophys Res Commun. 1997 Jun 27;235(3):533-8
references.pmid: 9207191
references.citation: Shock. 2006 Aug;26(2):201-9
references.pmid: 16878030
references.citation: J Pharm Sci. 2004 May;93(5):1154-64
references.pmid: 15067692
references.citation: J Biol Chem. 2002 Oct 4;277(40):37896-903
references.pmid: 12138127
references.citation: J Pharmacol Exp Ther. 2006 Jul;318(1):99-107
references.pmid: 16603672
references.citation: Arch Dermatol. 1991 Sep;127(9):1339-45
references.pmid: 1892402
references.citation: Physiol Rev. 2006 Oct;86(4):1309-79
references.pmid: 17015491
references.citation: J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S59-69
references.pmid: 15968265
references.citation: Microb Pathog. 1998 Feb;24(2):101-9
references.pmid: 9480792
references.citation: Pain. 2004 Oct;111(3):278-285
references.pmid: 15363871
references.citation: J Invest Dermatol. 2006 Aug;126(8):1784-91
references.pmid: 16543895
references.citation: Exp Dermatol. 2000 Feb;9(1):1-10
references.pmid: 10688368
references.citation: J Med Chem. 2003 Dec 18;46(26):5651-62
references.pmid: 14667219
references.citation: Clin Exp Rheumatol. 2006 Jan-Feb;24(1 Suppl 40):S1-6
references.pmid: 16466619
references.citation: Am J Physiol. 1999 Dec;277(6):C1050-7
references.pmid: 10600756
references.citation: J Immunol. 1999 Sep 15;163(6):3449-58
references.pmid: 10477617
references.citation: Neurology. 2004 Jan 27;62(2):212-7
references.pmid: 14745056
references.citation: Br J Dermatol. 1981 Oct;105(4):405-13
references.pmid: 6271161
references.citation: J Invest Dermatol. 2004 Feb;122(2):497-502
references.pmid: 15009736
references.citation: Biochem Biophys Res Commun. 2000 Mar 16;269(2):401-5
references.pmid: 10708565
references.citation: Br J Dermatol. 1998 Mar;138(3):502-5
references.pmid: 9580808
references.citation: Int J Dermatol. 1997 Apr;36(4):266-71
references.pmid: 9169323
references.citation: J Leukoc Biol. 1995 Mar;57(3):440-9
references.pmid: 7533819
references.citation: Acta Derm Venereol. 1998 Mar;78(2):123-6
references.pmid: 9534890
references.citation: Nature. 2002 Sep 5;419(6902):77-81
references.pmid: 12214235
references.citation: J Invest Dermatol. 2005 Jun;124(6):1318-25
references.pmid: 15955110